Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/Phase 2, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of SAR444836, an Adeno-associated Viral Vector-mediated Gene Transfer of Human Phenylalanine Hydroxylase, in Adult Participants With Phenylketonuria

NCT05972629 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05972629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05972629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/Phase 2, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of SAR444836, an Adeno-associated Viral Vector-mediated Gene Transfer of Human Phenylalanine Hydroxylase, in Adult Participants With Phenylketonuria
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 7, 2023
Completion date
April 2, 2030
Enrollment
32 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria